Healthscope agrees to sell Asian pathology operations for $279m

Company News

by Anna Napoli

Healthscope (ASX:HSO) has agreed to sell its Asian pathology operations in Singapore, Malaysia and Vietnam for $279 million to private equity firm TPG Capital Asia.

The private healthcare provider expects to book a gain on sale of around $165 million. Proceeds of the sale will be used to pay down debt and fund Healthscope’s expansion pipeline.

The Asian pathology operations contributed earnings (EBITDA) of $18.2 million in Financial Year 17 and $9.6 million in the first half of 2018.

Healthscope MD and CEO, Gordon Ballantyne says the outcome realises significant value for Healthscope shareholders following a tough and competitive sales process.

Shares in Healthscope (ASX:HSO) are trading down 0.67 per cent to $2.21.

Anna Napoli

Finance News Network
Anna joined FNN February 2018 and also works with Channel 7 as a freelance producer. Anna has also worked as a lawyer and lecturer. She has also presented news updates for interstate news with Southern Cross Austereo.